Cite
HARVARD Citation
Solh, M. et al. (2020). Improved Post remission survival of non- favorable risk Acute Myelogenous Leukemia (AML) patients following initial remission induction therapy with FLAG+/-Idarubicin versus 3 + 7 (Anthracycline + Cytarabine). Leukemia research. p. . [Online].